Facebook Pixel Countering Obesity with Drugs Vs Viable Alternatives | Bio Spectrum - business - Magzter.comでこの記事を読む
Magzter GOLDで無制限に

Magzter GOLDで無制限に

10,000以上の雑誌、新聞、プレミアム記事に無制限にアクセスできます。

$149.99
 
$74.99/年

試す - 無料

Countering Obesity with Drugs Vs Viable Alternatives

Bio Spectrum

|

BioSpectrum India June 2025

A sizable obese population in India is a free ground for multinational pharma companies to launch various anti-obesity drugs.

Countering Obesity with Drugs Vs Viable Alternatives

Let aside the affordability issue, these drugs can be a game changer. However, severe side effects lurk in the background. Alternative treatment and fundamental lifestyle changes can be seen as an alternative mode to counter obesity. Let's examine the available and prospective obesity therapeutics.

The current state of obesity in India is alarming. As was evident from Prime Minister Narendra Modi's 119th Maan Ki Baat, where he cautioned against the rise in obesity cases that have doubled in the last few years. A major concern during his speech was how children are getting affected more. Union Minister Dr Jitendra Singh, a renowned Diabetologist, also raised alarms while underscoring the urgent need for a multifaceted and collective approach to combat the growing obesity crisis in India.

India's stint with obesity started in the last 20th century with people getting addicted to sugary drinks, junk foods etc. Rapid urbanisation, economic development, lifestyle changes and less physical activity all contributed to a rise in the obese population. Obesity is linked with stigma, and many encounter fat shaming. It leads to psychological stress. This apart, an obese person is vulnerable to various health issues like heart disease, type 2 diabetes, high blood pressure, cancer, sleep apnea, etc.

Launch of anti-obesity drugs

Seeing this as a strategy to market anti-obesity drugs, many multinational pharmaceutical companies are in a rat race to launch various products. With the launch of weight-loss drugs in the Indian market, the debate around pharmacological obesity treatment has intensified.

Seeking an opportunity, the US pharma major, Eli Lilly, recently launched Mounjaro. It is a single-dose vial presentation and has received marketing authorisation from the Central Drugs Standard Control Organisation (CDSCO). The company went ahead and also launched a campaign to combat the associated stigma with obesity.

Bio Spectrum からのその他のストーリー

Bio Spectrum

Bio Spectrum

Can India's CDMOS Lead the Next Biopharma Wave?

India's Contract, Development, and Manufacturing Organisation (CDMO) sector is projected to grow from $3-3.5 billion today to $22-25 billion by 2035, noted Boston Consulting Group (BCG).

time to read

8 mins

March 2026

Bio Spectrum

Bio Spectrum

Telangana turns catalyst for innovation

Telangana is at a pivotal moment in its journey as a global life sciences hub.

time to read

6 mins

March 2026

Bio Spectrum

Bio Spectrum

Is AI the New Weapon in the Fight to End TB?

A report released at the India AI Impact Summit 2026, organised by the Government of India, reveals that artificial intelligence (AI) is being successfully deployed at scale across India’s public healthcare system to address the growing burden of tuberculosis (TB).

time to read

2 mins

March 2026

Bio Spectrum

Bio Spectrum

ChemWerth on-boards Chandrakanth Reddy as new GSM to increase generic API footprint in India

US-based ChemWerth, Inc., a global leader in generic active pharmaceutical ingredient (API) development and supply, continues to expand its footprint and strengthen its position in the Indian market.

time to read

1 min

March 2026

Bio Spectrum

Bio Spectrum

Beyond the Glass Ceiling: Women-Led Companies Shaping India's Health Economy

Over the past decade, women entrepreneurs have gained strong ground in India's healthcare sector, building ventures in diagnostics, FemTech, biotech, and care delivery.

time to read

5 mins

March 2026

Bio Spectrum

Bio Spectrum

"There needs to be a collaborative effort between innovators and policymakers to create frameworks that ensure safety without stifling progress"

Started in 2021, Decode Age, one of the pioneers in Longevity Research in India, entered its next phase of growth following its Pre-Series A funding round, led by Granules India.

time to read

5 mins

March 2026

Bio Spectrum

Bio Spectrum

Rainbow Children's Medicare appoints Abrarali Dalal as Chief Executive Officer

Rainbow Children's Medicare, a leading provider of paediatrics, perinatal, and women's healthcare services in India, has announced the appointment of Abrarali Dalal as Chief Executive Officer, effective from January 20, 2026.

time to read

1 min

March 2026

Bio Spectrum

Bio Spectrum

Haleon ropes in Kedar Lele as President for India Subcontinent

Haleon, a British multinational consumer healthcare company has announced the appointment of Kedar Lele as President for India Subcontinent (ISC), effective January 2026.

time to read

1 min

March 2026

Bio Spectrum

Bio Spectrum

Centre revises Startup Recognition Framework to strengthen Startup India Action Plan

The government of India has revamped the Startup Recognition Framework to further strengthen the Startup India Action Plan and take forward the Prime Minister's vision of positioning India as a global innovation powerhouse, manufacturing-led economy and hub for emerging tech.

time to read

1 min

March 2026

Bio Spectrum

Bio Spectrum

"In the coming 5 years from now, no Indian CROS will grow or survive without the use of AI"

In January 2026, Ahmedabad-based Veeda Lifesciences announced a strategic leadership transition that marks a new chapter in the company's evolution.

time to read

5 mins

March 2026

Listen

Translate

Share

-
+

Change font size